**[394] ENHANCING INTERVENTIONAL VASCULAR PROCEDURES WITH B-LASER™, A HYBRID LASER & BLADE TECHNOLOGY  BY EXIMO MEDICAL**

**Yossi Muncher1, 1 Eximo Medical Ltd.**

**Enhancing Interventional Vascular Procedures with B-Laser™, a Hybrid Laser & Blade Technology**

**By Eximo Medical (BioMed 2016)**

* **Investment Rational**

B-Laser™ , a safe and efficient hybrid catheter combining short-pulse laser at 355 nm wavelength with a mechanical blunt blade, designated for endoluminal therapeutic interventions (starting with PAD and Lead Extraction (LE)) addressing $1.8B market. Company successfully completed 20 subjects study, backed-up by Accelmed VC and leaded by seasoned management with over 60 years of medical device experience.

* **Business Strategy**

The company’s first priority is the US market for PAD and LE followed by marketing in EU and other markets. The plan is to have direct marketing in US and specific geographies OUS (with strategic collaboration), and distribution in others. The scope does not yet include the extension of indication to CAD and to thrombectomy and vein indications.

* **Core Technology**

The B-Laser™ is a “Hybrid Catheter” that combines optic fibers that deliver 355nm energy from a solid-state laser and a mechanical blunt blade to resect deposits within blood vessels.

Current laser systems may vaporize both plaque and the vascular wall, while the BlaserTM is clinically selective for the fibrotic lesion, and can de-bulk plaques better than the competitors.

* **Product Profile/Pipeline**

Eximo’s B-Laser™ catheters were used with 100% success both efficiently and safely. PAD market in the US is $1.3B and the LE market, $0.5B, is showing dynamic growth of 15% per year.

Eximo Pipeline Applications are: Gastro Intestinal (GI), Urology, CAD and Thrombectomy. The company expects CE for PAD in Q4 2016 and 510(k) in Q3 2017.

* **What's Next?**

Recently, Eximo completed round A investment (Accelmed and others). After CE /FDA approvals, the company will conduct post marketing clinical studies to substantiate its added value in different applications and initiate new studies for additional indications with additional HR growth, with additional funding, during 2016-2017 to support achievement of Company goals and development of New Catheters.